Eli Lilly and Company (NYSE:LLY) Stock Price Up 0.5%

Eli Lilly and Company (NYSE:LLY)’s stock price rose 0.5% on Friday . The company traded as high as $915.54 and last traded at $913.72. Approximately 504,744 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 2,914,000 shares. The stock had previously closed at $909.04.

Wall Street Analyst Weigh In

LLY has been the topic of a number of analyst reports. Argus upped their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. The Goldman Sachs Group increased their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. BMO Capital Markets increased their target price on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Jefferies Financial Group increased their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday. Finally, Bank of America restated a “buy” rating and set a $1,000.00 target price on shares of Eli Lilly and Company in a report on Monday. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $812.72.

Eli Lilly and Company Stock Performance

The stock has a market cap of $867.09 billion, a P/E ratio of 134.57, a PEG ratio of 1.97 and a beta of 0.36. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The stock has a fifty day simple moving average of $807.55 and a 200-day simple moving average of $735.35.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company’s revenue was up 26.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.62 earnings per share. Equities analysts expect that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 92,563 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $809.21, for a total value of $74,902,905.23. Following the sale, the insider now owns 98,556,247 shares of the company’s stock, valued at approximately $79,752,700,634.87. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, major shareholder Lilly Endowment Inc sold 92,563 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $809.21, for a total value of $74,902,905.23. Following the sale, the insider now owns 98,556,247 shares of the company’s stock, valued at approximately $79,752,700,634.87. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the transaction, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. In the last quarter, insiders have sold 789,704 shares of company stock valued at $672,385,964. 0.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of LLY. Trexquant Investment LP bought a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $3,874,000. Morningstar Investment Services LLC boosted its stake in shares of Eli Lilly and Company by 112.8% during the 3rd quarter. Morningstar Investment Services LLC now owns 1,741 shares of the company’s stock worth $948,000 after acquiring an additional 923 shares during the period. Ancora Advisors LLC boosted its stake in shares of Eli Lilly and Company by 2.9% during the 3rd quarter. Ancora Advisors LLC now owns 6,935 shares of the company’s stock worth $3,725,000 after acquiring an additional 198 shares during the period. Gotham Asset Management LLC boosted its stake in Eli Lilly and Company by 111.3% in the 3rd quarter. Gotham Asset Management LLC now owns 7,386 shares of the company’s stock valued at $3,967,000 after purchasing an additional 3,891 shares during the period. Finally, Kinloch Capital LLC boosted its stake in Eli Lilly and Company by 25.8% in the 3rd quarter. Kinloch Capital LLC now owns 717 shares of the company’s stock valued at $385,000 after purchasing an additional 147 shares during the period. 82.53% of the stock is currently owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.